Metronidazole was carcinogenic in mice and rats in chronic studies, so unnecessary use of metronidazole should be avoided.
Metronidazole may cause convulsive seizures and peripheral neuropathy characterized mainly by numbness, tingling, or parasthesia of an extremity, have been reported rarely in patients treated with Nirmet. Peripheral neuropathy is usually reversible if metronidazole is discontinued but may persist in patients who receive prolonged therapy or higher than recommended dosage of the drug.
Metronidazole intravenous infusion should be used with caution in patients receiving corticosteroids and in patients with renal disease cardiovascular disease and predisposed to edema because the infusion contains sodium 0.326%.
Metronidazole intravenous infusion may result in oral, vaginal, or intestinal candidiasis. If superinfection or suprainfection occurs, appropriate therapy should be instituted.
Metronidazole intravenous infusion may cause leucopenia, so metronidazole should be used with care in patients with evidence of or history of blood dyscrasia. Total and differential leucocyte count are recommended before and after therapy.
Patients with severe hepatic disease metabolized metronidazole slowly, with resultant accumulation of metronidazole and its metabolites in the plasma. Accordingly, for such patients, doses below those usually recommended should be administered cautiously.
Effects on the Ability to Drive or Operate Machinery: Patients should be warned about the potential for drowsiness, dizziness, confusion, hallucinations, convulsions or transient visual disorders, and advised not to drive or operate machinery if these symptoms occur during therapy of Metronidazole Injection.